CURA Diagnostics Unveils Xpeedy A20: Revolutionizing Automated Sample Preparation for LC/MS/MS Analysis

First Client to Implement Cutting-Edge Solution for Urine Toxicology Tests in August

Greater Boston Area, July 21, 2023 - CURA Diagnostics, Inc., a leading innovator in medical diagnostics, will make a groundbreaking leap in laboratory automation with the launch of their flagship product, Xpeedy A20. This automated sample preparation solution for Triple Quadrupole LC/MS/MS analysis promises to revolutionize the way drugs of abuse tests are conducted, providing unmatched efficiency, accuracy, and reliability for clinical laboratories. The company plans to install Xpeedy A20 in its first client's site next month, marking the beginning of a new era in advanced diagnostic technology.

Xpeedy A20 boasts an impressive array of features that will reshape the landscape of laboratory workflows. The system is equipped with dual arms, one functioning as a 2-channel capper/decapper and the other as a 2-tip liquid dispenser. This integration allows for seamless, robotic liquid handling from sample tubes to fully prepared plates, ready for downstream testing. Its adaptability ensures easy customization, enabling laboratories to effortlessly integrate the product into their existing processes.

The complete workflow solution provided by Xpeedy A20 includes the instrument itself, consumables, software, and comprehensive application support. This holistic approach simplifies the adoption of the technology and also significantly enhances efficiency and productivity within the laboratory environment. By streamlining sample preparation, the product can drastically reduce total costs, minimize human errors, and improve data quality, ultimately leading to faster and more accurate results for medical professionals and patients.

Dr. Jia He, CEO of CURA Diagnostics, expressed her excitement about the potential impact of Xpeedy A20 on the diagnostic industry. "With Xpeedy A20, we aim to empower laboratories with a state-of-the-art solution that not only simplifies their processes but also elevates the standard of care they can provide to their patients."

As part of CURA's long-term vision, the company also announced its plans to launch a second product—a molecular Point-of-Care diagnostic solution—early next year. This cutting-edge product will revolutionize point-of-care testing, offering rapid and accurate information within just 90 minutes. The platform has been specially tailored to meet the clinical needs of primary care physicians and specialists alike, providing a unique and customizable test panel for more personalized patient care.

CURA Diagnostics' unwavering commitment to research and development has positioned the company as a pioneer in the diagnostic industry. With the August launch of Xpeedy A20 and the anticipated launch of their second product in early 2024, the company is poised to drive significant advancements in medical diagnostics, making healthcare more accessible and efficient for patients and healthcare providers alike.